Subtype
Malignant Head and Neck Mucosal Neoplasm
CI-CAN-00001135Explore in graph →
163 active trials3 evidence items
- NCIt
- C214952
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001135Explore in graph →
Clinical trials
466 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (63)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04564989 | Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC | recruiting | — | 220 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05268614 | Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma | recruiting | Phase 2 | 250 | University of FloridaOTHER | 1 | Apr 24, 2026 |
| NCT05893888 | A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers | recruiting | Phase 2 / Phase 3 | 40 | Privo TechnologiesINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07209189 | Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)((NeoScorch HN)) | recruiting | Phase 2 | 75 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06356272 | Oropharynx (OPX) Biomarker Trial | recruiting | — | 560 | Mayo ClinicOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03114462 | Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer | recruiting | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05307939 | A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06097468 | Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC) | recruiting | Phase 1 / Phase 2 | 40 | University of California, San FranciscoOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07423078 | Window of Opportunity in Preserving Laryngeal Function Trial(WOLF) | recruiting | Phase 2 | 87 | Matthew SpectorOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06323460 | Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer | recruiting | Phase 2 | 45 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT05539638 | The Role of Circulating Tumour DNA in Head and Neck Cancer | recruiting | — | 250 | University of EdinburghOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06030440 | De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck(DIREKHT2) | recruiting | Phase 2 / Phase 3 | 508 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06868433 | TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer | recruiting | Phase 1 | 40 | Emory UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07044635 | Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.(RAD RAPTORS) | recruiting | Phase 2 | 42 | University of UtahOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06336941 | "Ultra-High Frequency intraOral UltraSonography of the TONgue" (HOUSTON)(HOUSTON) | recruiting | N/A | 400 | University of PisaOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07063212 | A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06636734 | Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial | recruiting | Phase 2 | 28 | Emory UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT01473784 | Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck | recruiting | N/A | 600 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05962242 | HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma(HN001) | recruiting | Phase 2 | 90 | University of VirginiaOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05894083 | A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze) | recruiting | Phase 2 | 150 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06319963 | A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer | recruiting | Phase 1 / Phase 2 | 72 | Theravectys S.A.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07371611 | Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma | recruiting | Phase 3 | 104 | Qunxing Li,MDOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07343271 | Dual-energy CT vs. MRI in the Evaluation of Squamous Cell Carcinomas of the Oral Cavity and Oropharynx(DECT-CEco) | recruiting | — | 30 | University Hospital, Strasbourg, FranceOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT03215719 | Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma | recruiting | Phase 2 | 120 | NYU Langone HealthOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05333523 | Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.(PRIMO) | recruiting | Phase 3 | 242 | Radboud University Medical CenterOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06088381 | Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)(SAVAL) | recruiting | Phase 2 | 61 | University of Maryland, BaltimoreOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT06914999 | Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer | recruiting | Early Phase 1 | 20 | Emory UniversityOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT07111455 | Prospective Cohort Study on Oral Microbiome Changes in Patients With Locally Advanced Oral Squamous Cell Carcinoma Following Neoadjuvant Chemoimmunotherapy | recruiting | — | 32 | Zhujiang HospitalOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07180901 | Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck Cancer(PRONTO-HN) | recruiting | N/A | 85 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07133958 | A Bidirectional Observational Clinical Study of NAIC in the Treatment of Tumor Regression Patterns in LA-OSCC and LA-OPSCC | recruiting | — | 35 | Zhujiang HospitalOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT06307015 | De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE)(DE-RADIATE) | recruiting | N/A | 25 | Royal North Shore HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05774483 | Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative(SECOND N0) | recruiting | N/A | 508 | Tata Memorial HospitalOTHER_GOV | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06061705 | Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies(iMonitORL) | recruiting | N/A | 100 | Fondation Hôpital Saint-JosephOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06321003 | SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography(SYMILIS OCT) | recruiting | — | 200 | University of PalermoOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT05144698 | RAPA-201 Therapy of Solid Tumors | recruiting | Phase 1 / Phase 2 | 37 | Rapa Therapeutics LLCINDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT05451303 | Detection of Oral and Throat Cancers Using OralViome Cancer Testing System | recruiting | — | 475 | ViomeINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06174428 | Validity of Viome's Oral/throat Cancer Test | recruiting | — | 1,000 | ViomeINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06380686 | Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome(HEAT) | recruiting | — | 120 | AIO-Studien-gGmbHOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT06137378 | European Larynx Organ Preservation Study (ELOS) [MK-3475-C44](ELOS) | recruiting | Phase 2 | 140 | University of LeipzigOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06589609 | Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer | recruiting | Phase 1 | 12 | BlueSky Immunotherapies GmbHINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05798793 | Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma(NEOPCOSCC) | recruiting | Phase 3 | 309 | Hospital of Stomatology, Wuhan UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05098119 | Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) | recruiting | Phase 2 | 43 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT04104945 | p16+ Oropharyngeal Cancer Radiation Optimization Trial Reducing Elective Treatment Volumes (PROTEcT)(PROTEcT) | recruiting | N/A | 32 | AHS Cancer Control AlbertaOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05069857 | Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients | recruiting | Phase 2 | 46 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05125055 | Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC | recruiting | Phase 2 / Phase 3 | 80 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05918510 | Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus | recruiting | — | 142 | Regina Elena Cancer InstituteOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05862168 | Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial | recruiting | Phase 2 | 30 | Weijia Fang, MDOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05872880 | TPExtreme Induced Chemotherapy Followed by Surgery and Radiotherapy in the Oral Carcinoma. | recruiting | — | 124 | Xiangya Hospital of Central South UniversityOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT05611515 | Treatment of Early Supraglottic Squamous Cell Carcinoma With Advance Technologies(SUPRA-QoL) | recruiting | — | 108 | Centre Hospitalier Universitaire UCLouvain NamurOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT04220749 | Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma | recruiting | Phase 2 | 68 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Sep 4, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Apr 28, 2026source: clinicaltrials